The application of sorafenib in the treatment of early brain injury after subarachnoid hemorrhage

A technology for subarachnoid space and brain injury, which can be applied to cardiovascular system diseases, antineoplastic drugs, active ingredients of heterocyclic compounds, etc., can solve the problems of lack of clinical treatment methods, and achieve the effect of reducing cerebral edema

Inactive Publication Date: 2011-12-21
THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] At present, there is a lack of corresponding clinical treatment methods for EBI after aneurysmal SAH clinically, and at this stage there is an urgent need for a dru

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The application of sorafenib in the treatment of early brain injury after subarachnoid hemorrhage
  • The application of sorafenib in the treatment of early brain injury after subarachnoid hemorrhage
  • The application of sorafenib in the treatment of early brain injury after subarachnoid hemorrhage

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0048] Materials and methods

[0049] 1. Materials

[0050] (1) Material

[0051] The main reagents and drugs include: rabbit anti-matrix metalloproteinase-9 (MMP-9) antibody was purchased from Beijing Boaosen Biotechnology Co., Ltd.; rabbit anti-vascular endothelial growth factor (VEGF) antibody was purchased from Beijing Boaosen Biotechnology Co., Ltd. ; Rabbit anti-cyclooxygenase 2 (COX-2) antibody was purchased from Cayman, USA; TUNEL cell apoptosis detection kit was purchased from Wuhan Boster Bioengineering Co., Ltd.; Evans Blue (EB) was purchased from Sigma, USA Company; dimethyl sulfoxide (DMSO) was purchased from Sigma, USA; BAY 43-9006 was purchased from Bayer, Germany, etc. The nuclear-cytoplasmic protein preparation kit was purchased from Beijing Pulilai Gene Technology Co., Ltd.; The chemiluminescent EMSA kit was purchased from Pierce, USA.

[0052] Dissolve BAY 43-9006 in the mixed liquid that is mixed with polyoxyethylene castor oil and 95% ethanol in a vol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of sorafenib shown in a formula (I) in the preparation of a medicinal composition for treating early brain injury (EBI) after subarachnoid hemorrhage (SAH). Due to the adoption of the sorafenib, the activation of Raf-1/ERK1/2 and Raf-1/NF-kappa B signal paths can be restrained, hydrocephalus degrees, the permeability increase degrees of a blood brain barrier and cell apoptosis degrees can be reduced, a certain treatment effect can be displayed, and a new path can be provided for preventing and treating the EBI after the SAH.

Description

technical field [0001] The invention belongs to the technical field of new uses of medicines, and specifically relates to the application of sorafenib in the treatment of early brain injury after aneurysmal spontaneous subarachnoid hemorrhage. Background technique [0002] The annual incidence of spontaneous subarachnoid hemorrhage (SAH) is about 6-16 / 100,000 people, accounting for about 6-8% of the total incidence of stroke. Intracranial aneurysm rupture is the main cause of spontaneous SAH. reason. With the deepening of research, people gradually realize that early brain injury (early brain injury, EBI) may be the primary cause of poor prognosis in SAH patients, and the exploration of the mechanism of EBI may be the main direction of SAH research in the future. The so-called EBI refers to the direct injury of the whole brain tissue within 72 hours after SAH, including the death of brain tissue cells, the destruction of blood-brain barrier, cerebral edema, acute CVS, micro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/44A61P9/00A61P35/00A61P9/10
Inventor 王中陈罡张健周岱
Owner THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap